This study compared the frequency of variant cytochrome P450 2C9 (CYP2C9) alleles and warfarin S/R concentration ratio in patients who required low-dose (<2.5 mg/day) and average-dose (5 ± 0.5 mg/day) warfarin. Patients who achieved a therapeutic international normalized ratio were recruited from the Atlanta Veterans Affairs Medical Center anticoagulation clinic. CYP2C9*2 and *3 alleles were determined by validated Taqman allelic discrimination assays. Warfarin S and R concentrations were determined by chiral capillary electrochromatography with electrospray ionization mass spectrometry. At least 1 variant allele was found in 66.7% and 22.2% of patients in the low-dose and average-dose groups, respectively (P = .001, χ2). The warfarin S/R concentration ratio was 0.665 (range, 0.162-3.58) and 0.452 (range, 0.159-2.36) for patients receiving low-dose and average-dose therapy, respectively ( P = .097). A warfarin requirement of <2.5 mg/day and an elevated warfarin S/R concentration ratio were each associated with a higher frequency of variant CYP2C9 alleles.
Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., Hylek E.The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126: 204S-233S.
2.
Chan E., McLachlan AJ, Pegg M., MacKay AD, Cole RB, Rowland M.Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with racwarfarin. Br J Clin Pharmacol.1994;37:563-569.
3.
Henne KR, Gaedigk A., Gupta G., Leeder JS, Rettie AEChiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr B. 1998;710:143-148.
4.
Miners JO, Birkett DJCytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J ClinicalPharmacol.1998;45:525-538.
5.
Kaminsky LS, Zhang Z-Y.Human P450 metabolism of warfarin. Pharmacol Ther.1997;73:67-74.
6.
Lee CR, Goldstein JA, Pieper JACytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12:251-263.
7.
Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KRImpaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994;4:39-42.
8.
Rettie AE, Haining RL, Bajpai M., Levy RHA common genetic basis for idiosyncratic toxicity of warfarin and phenytoin . Epilepsy Res.1999;35:253-255.
9.
Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 1997;7:361-367.
10.
Dickmann LJ , Rettie AE, Kneller MB, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol.2001 ;60:382-387.
11.
Goldstein JAPolymorphisms in the human CYP2C subfamily . Drug Metab Rev.2002;34:5.
12.
Imai J., Ieiri I., Mamiya K., et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene. Pharmacogenetics. 2000;10:85-89.
13.
Kidd RS, Curry TB, Gallagher S., Edeki T., Blaisdell J., Goldstein J.Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001 ;11:803-808.
14.
Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002 ; 287:1690-1698.
15.
Sachse C., Brockmoller J., Bauer S., Roots I. Functional significance of a C—>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol.1999;47:445-449.
Zheng J., Norton D., Shamsi SAFabrication of internally tapered capillaries for capillary electrochromatography electrospray ionization mass spectrometry. Anal Chem.2006;78:1323-1330.
18.
Zheng J., Shamsi SACombination of chiral capillary electrochromatography with electrospray ionization mass spectrometry: method development and assay of warfarin enantiomers in human plasma. Anal Chem.2003;75:6295-6305.
19.
Aithal GP, Day CP, Kesteven PJ, Daly AKAssociation of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717-719.
20.
Scordo MG, Pengo V., Spina E., Dahl ML, Gusella M., Padrini R.Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther.2002;72:702-710.
21.
Takahashi H. , Kashima T., Nomizo Y., Muramoto N., Shimizu T.Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes . Clin Pharmaol Ther. 1998;63:519-528.
22.
Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RHThe risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Int Med.1996;124:970-979.
23.
Kamali F., Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther.2004;75:204-212.
24.
Takahashi H. , Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. PharmacogenetGenomics. 2006; 16:101-110.
25.
Yasar U., Aklillu E., Canaparo R., et al. Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations. Eur J Clin Pharmacol.2002;58:555-558.
26.
Allabi AC, Gala JL, Horsmans Y.CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. PharmacogenetGenomics. 2005;15:779-786.
27.
Allabi AC, Gala JL, Horsmans Y., et al. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmaol Ther. 2004;76:113-118.
28.
Gage BF, Milligan PE, Banet GA, Duncan JR, McLeod HLUse of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost.2004;91:87-94.
29.
Joffe HV, Xu R., Johnson FB, Longtine J., Kucher N., Goldhaber SZWarfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost.2004;91:1123-1128.
30.
Takahashi H. , Wilkinson GR, Caraco Y., et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients . Clin Pharmaol Ther. 2003;73:253-263.
31.
Nakajima M. , Yokoi T., Mizutani M., et al. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem.1999;125:803-808.
